Dual Targeting of Innate and Adaptive Checkpoints on Tumor Cells Limits Immune Evasion

Area of Science:

• Immunology
• Oncology
• Cancer immunotherapy

Background:

• CD47 and PD-L1 are tumor cell surface proteins that inhibit immune responses.
• CD47 blocks phagocytosis, while PD-L1 suppresses T cell activity.
• The coordinated roles of CD47 and PD-L1 in immune evasion are not well understood.

Purpose of the Study:

• To investigate the coordinated function of CD47 and PD-L1 in tumor immune evasion.
• To evaluate the therapeutic potential of simultaneously blocking CD47 and PD-L1.
• To elucidate the mechanisms underlying dual blockade efficacy.

Main Methods:

• Utilized a bispecific antibody targeting both CD47 and PD-L1 on tumor cells.
• Assessed tumor targeting and therapeutic efficacy in preclinical models.
• Analyzed immune responses, including DNA sensing, dendritic cell cross-presentation, and T cell activity.
• Investigated the synergistic effects of dual blockade with chemotherapy.

Main Results:

• CD47 and PD-L1 coordinately suppress innate and adaptive immune sensing.
• A bispecific antibody targeting both CD47 and PD-L1 demonstrated superior tumor targeting and efficacy compared to monotherapy.
• Dual blockade enhanced DNA sensing, dendritic cell cross-presentation, and anti-tumor T cell responses.
• Chemotherapy combined with the bispecific reagent led to improved tumor control.

Conclusions:

• Tumor cells exploit both CD47 and PD-L1 to evade immune surveillance.
• Simultaneous targeting of CD47 and PD-L1 on tumor cells is a promising immunotherapy strategy.
• Dual blockade enhances innate and adaptive anti-tumor immunity.
• Combination therapy with chemotherapy offers synergistic tumor control.